SBIR-STTR Award

Microwave phased array for hyperthermia cancer theraphy
Award last edited on: 5/22/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$550,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Everette C Burdette

Company Information

Labthermics Technologies Inc

701 Devonshire Drive
Champaign, IL 61820
   (217) 351-7722
   kouzman@labthermics.com
   www.labthermics.com
Location: Single
Congr. District: 13
County: Champaign

Phase I

Contract Number: 1R43CA044078-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1986
Phase I Amount
$50,000
The goal of this project is to develop a prototype microwave phased array applicator for local tumor hyperthermia therapy. The therapeutic effectiveness of ionizing radiation therapy can be improved by the focused application of heat to the tumor. The use of microwaves for the generation of local hyperthermia has been successfully applied in both animal and clinical studies. However, current microwave applicators heat only superficial tumors and must be mechanically moved in order to change the power distribution in the tumor and surrounding normal tissues. The specific aims of this Phase I study are to develop new techniques for producing local tumor hyperthermia using microwaves.Preliminary studies have resulted in a new design for a microwave phased array hyperthermia applicator. The Phase I studies will allow development of this existing design into a working prototype microwave hypertherrnia applicator system. This applicator system will consist of a microwave phased array applicator, a microwave power amplifier and distribution network, and a computer control system for the applicator. This new microwave phased array applicator system will have the capability of focusing microwave energy more effectively in tissue than presently available clinical devices and the location of the focus will be electronically rather than mechanically scanned in order to produce a uniform tumor temperature distribution without overheating surrounding normal tissues. The results of the Phase I studies will provide a basis for human clinical trials of combined radiation and hyperthermia therapy.National Cancer Institute (NCI)

Phase II

Contract Number: 2R44CA044078-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1988
(last award dollars: 1989)
Phase II Amount
$500,000

The goal of this project is to develop a clinical microwave phased array applicator system for hyperthermia therapy in deep-seated tumors. The proposed work seeks to continue development of a novel phase-controlled system for hyperthermia induction. The therapeutic effectiveness of ionizing radiation therapy can be improved by the focused application of heat to the tumor region. The use of microwaves for the generation of local and regional hyperthermia has been successfully applied in clinical studies. However, current designs for microwave applicators heat only superficial tumors and must be mechanically moved in order to change power distribution in the tumor and surrounding normal tissues. The specific aims of the proposed Phase II program are designed to complete development of new techniques for producing tumor hyperthermia using microwaves.Phase I efforts have resulted in new designs for microwave phased array hyperthermia applicators and development of working laboratory prototype applicators utilizing microstrip patches and waveguides. In Phase II, a clinical prototype system will be developed consisiting of phased array applicators, solid-state power amplifiers, computer control system, thermometry mapping, and human-engineered interactive operation. This new phased array system will have the capability of focusing energy more effectively in tissue than presently available clinical devices and the location of the focus will be electronically rather than mechanically scanned to produce a uniform tumor temperature distribution without overheating surrounding normal tissues. The developed system will be tested in phantoms and experimental animal models.National Cancer Institute (NCI)